<DOC>
	<DOCNO>NCT01599507</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy safety FG-4592 correction anemia non-dialysis chronic kidney disease patient .</brief_summary>
	<brief_title>Study FG-4592 Subjects With Chronic Kidney Disease China</brief_title>
	<detailed_description>Dose range study two consecutive dose escalation cohort . The study objective demonstrate FG-4592 effective correction anemia chronic kidney disease patient .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Age 18 75 year 2 . Subject voluntarily sign date informed consent form 3 . Chronic Kidney Disease , receive dialysis 4 . Hemoglobin ( Hb ) value 4 screen visit mean Hb must &lt; 10g/dL 5 . Aminotransferase level ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] ) total bilirubin must ≤ upper limit normal ( ULN ) screen period 6 . Serum alkaline phosphatase ( ALP ) ≤2x ULN screen period . Subjects serum ALP value 1 x 2 x ULN may include bonespecific ALP ( BSAP ) also elevate &gt; ULN 7 . Total bilirubin value must ≤ULN screen period 8 . Serum folate vitamin B12 level low limit normal ( LLN ) 9 . Body weight : 40 100 kg ( dry weight ) inclusive 10 . Body mass index ( BMI ) : 16 38 kg/m2 inclusive 1 . Received erythropoiesisstimulating agent ( ESA ) epoetin alfa within 12 week prior Day 1 2 . Any clinically significant infection evidence underlie infection white blood cell count ( WBC ) &gt; ULN screen two separate occasion , 3 . Positive following : human immunodeficiency virus ( HIV ) ; hepatitis B surface antigen ( HBsAg ) ; antihepatitis C virus antibody ( antiHCV Ab ) 4 . History chronic liver disease 5 . New York Heart Association Class III IV congestive heart failure 6 . Chronic inflammatory disease glomerulonephritis could impact erythropoiesis ( e.g. , systemic lupus erythematosis , rheumatoid arthritis , celiac disease ) even currently remission 7 . Active chronic gastrointestinal bleeding , know coagulation disorder 8 . Hemoglobinopathy ( e.g. , homozygous sicklecell disease , thalassemia type , etc . ) 9 . Hematological disorder , include myelodysplastic syndrome , multiple myeloma , pure red cell aplasia 10 . History hemosiderosis , hemochromatosis , polycystic kidney disease , anephric 11 . Active hemolysis diagnosis hemolytic syndrome 12 . Known bone marrow fibrosis 13 . Uncontrolled symptomatic secondary hyperparathyroidism ( PTH &gt; 600ng/L ) 14 . Any prior organ transplantation 15 . Drugtreated gastroparesis , shortbowel syndrome , gastrointestinal condition may lead reduce absorption study drug 16 . Serum albumin &lt; 3 g/dL 17 . History alcohol drug abuse ; positive drug screen substance prescribe subject 18 . Prior treatment FG4592 19 . Use investigational medication treatment , carryover effect investigational treatment expect , screen visit , treatment followup period . 20 . Use traditional Chinese medicine ( TCM ) screen visit Day 1 plan use TCM study unless approve advance Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Renal</keyword>
</DOC>